Voluntary Exercise Prevents Cisplatin-Induced Muscle Wasting during Chemotherapy in Mice
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Voluntary Exercise Prevents Cisplatin-Induced Muscle Wasting during Chemotherapy in Mice. / Hojman, Pernille; Fjelbye, Jonas; Zerahn, Bo; Christensen, Jesper F; Dethlefsen, Christine; Lonkvist, Camilla K; Brandt, Claus; Gissel, Hanne; Pedersen, Bente Klarlund; Gehl, Julie.
In: PloS one, Vol. 9, No. 9, e109030, 2014, p. 1-10.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Voluntary Exercise Prevents Cisplatin-Induced Muscle Wasting during Chemotherapy in Mice
AU - Hojman, Pernille
AU - Fjelbye, Jonas
AU - Zerahn, Bo
AU - Christensen, Jesper F
AU - Dethlefsen, Christine
AU - Lonkvist, Camilla K
AU - Brandt, Claus
AU - Gissel, Hanne
AU - Pedersen, Bente Klarlund
AU - Gehl, Julie
PY - 2014
Y1 - 2014
N2 - Loss of muscle mass related to anti-cancer therapy is a major concern in cancer patients, being associated with important clinical endpoints including survival, treatment toxicity and patient-related outcomes. We investigated effects of voluntary exercise during cisplatin treatment on body weight, food intake as well as muscle mass, strength and signalling. Mice were treated weekly with 4 mg/kg cisplatin or saline for 6 weeks, and randomized to voluntary wheel running or not. Cisplatin treatment induced loss of body weight (29.8%, P < 0.001), lean body mass (20.6%, P = 0.001), as well as anorexia, impaired muscle strength (22.5% decrease, P < 0.001) and decreased glucose tolerance. In addition, cisplatin impaired Akt-signalling, induced genes related to protein degradation and inflammation, and reduced muscle glycogen content. Voluntary wheel running during treatment attenuated body weight loss by 50% (P < 0.001), maintained lean body mass (P < 0.001) and muscle strength (P < 0.001), reversed anorexia and impairments in Akt and protein degradation signalling. Cisplatin-induced muscular inflammation was not prevented by voluntary wheel running, nor was glucose tolerance improved. Exercise training may preserve muscle mass in cancer patients receiving cisplatin treatment, potentially improving physical capacity, quality of life and overall survival.
AB - Loss of muscle mass related to anti-cancer therapy is a major concern in cancer patients, being associated with important clinical endpoints including survival, treatment toxicity and patient-related outcomes. We investigated effects of voluntary exercise during cisplatin treatment on body weight, food intake as well as muscle mass, strength and signalling. Mice were treated weekly with 4 mg/kg cisplatin or saline for 6 weeks, and randomized to voluntary wheel running or not. Cisplatin treatment induced loss of body weight (29.8%, P < 0.001), lean body mass (20.6%, P = 0.001), as well as anorexia, impaired muscle strength (22.5% decrease, P < 0.001) and decreased glucose tolerance. In addition, cisplatin impaired Akt-signalling, induced genes related to protein degradation and inflammation, and reduced muscle glycogen content. Voluntary wheel running during treatment attenuated body weight loss by 50% (P < 0.001), maintained lean body mass (P < 0.001) and muscle strength (P < 0.001), reversed anorexia and impairments in Akt and protein degradation signalling. Cisplatin-induced muscular inflammation was not prevented by voluntary wheel running, nor was glucose tolerance improved. Exercise training may preserve muscle mass in cancer patients receiving cisplatin treatment, potentially improving physical capacity, quality of life and overall survival.
U2 - 10.1371/journal.pone.0109030
DO - 10.1371/journal.pone.0109030
M3 - Journal article
C2 - 25268807
VL - 9
SP - 1
EP - 10
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 9
M1 - e109030
ER -
ID: 135497003